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THE SETTING
An understanding of the pathophysiology of a
disease is crucial for the development and application
of interventions. This is particularly salient for diseases
which lack preventative therapies. Degenerative aortic
stenosis is one such condition. Interest in improving our
understanding of the biological processes governing
aortic stenosis is therefore intense. This has become
even more relevant in the current era of transcatheter
heart valves, with the increasing number of potential
candidates for intervention sharpening focus on the
healthcare burden posed by this chronic disease.1
Degenerative aortic stenosis is the prototypical
calcific valve disease, with complex biological processes
occurring over years before manifesting as a clinical
entity. Cellular injury, lipid deposition, and inflamma-
tion lead to valve interstitial cell differentiation and
expression of pro-osteogenic factors that drive calcium
deposition, ultimately resulting in outflow obstruction
due to valvular stenosis.2 Similarities have been drawn
between the early pathology of aortic stenosis and
atherosclerosis,3 yet seminal randomized controlled
trials of statin therapy failed to demonstrate benefit
with regard to aortic stenosis progression.4-6 Although
early calcification of the valve and coronary arteries may
be a common response to injury and inflammation, the
ultimate clinical effects are divergent. Progressive cal-
cification is the predominant pathological process
driving valve obstruction in aortic stenosis. In contrast,
coronary macrocalcification is associated with
stable atherosclerotic plaques that are less prone to
rupture and appears to be accelerated by statin therapy.7
Further work is therefore required to understand the
governing mechanisms and interactions of valvular and
coronary calcification.
THE STUDY
In this issue of the Journal of Nuclear Cardiology,
Nakamoto et al explore this relationship with a post hoc
analysis from their previously published prospective
18F-sodium fluoride (18F-NaF) positron emission
tomography-computed tomography (PET-CT) study.8,9
18F-NaF is the current focus of multiple cardiac
imaging studies, having previously been used as a bone
tracer in oncology. The radiotracer binds to hydroxya-
patite and serves as a marker of calcification activity in
multiple cardiovascular disease states. In particular,
increased 18F-NaF uptake has been demonstrated in
high-risk and culprit coronary and carotid plaques.9-12 It
is also associated with faster aortic stenosis disease
progression13,14 and bioprosthetic aortic valve degener-
ation.15 As such, there is appeal in using this imaging
biomarker to investigate calcification activity in both
aortic stenosis and coronary atherosclerosis.
The overall study cohort was comprised of 44
patients with known/suspected coronary artery disease,
recruited between June 2014 and December 2018, who
underwent computed tomography coronary angiography
(CTCA) and were found to have at least one coronary
atherosclerotic lesion. 18F-NaF PET-CT was performed
within 1 month of the CTCA. For this substudy, the
investigators retrospectively identified 25 patients with
evidence of early aortic valve calcification on CT (C
130 Hounsfield units) who did not have aortic stenosis
on echocardiography (peak aortic valve velocity\ 2m/
s). CTCA analysis included qualitative assessment for
high-risk coronary artery plaque, defined by the
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presence of low-density plaque (\30 Hounsfield units)
or positive remodeling (remodeling index[1.1). Aortic
valve calcium score, density, and 18F-NaF uptake were
quantified. Of the 25 patients, 11 underwent repeat
cardiac CT (35 ± 9 months) for assessment of aortic
valve disease progression.
At baseline, the mean aortic valve velocity was 1.4
± 0.3 m/s, while the median aortic valve calcium score
was 101 (11-171) Agatston units. The maximum aortic
valve tissue-to-background ratio (TBRmax) was 1.52 ±
0.18. At the patient level, 14 of 25 had at least one high-
risk plaque. At the lesion level, 20 of 90 plaques had at
least one high-risk feature. The median coronary cal-
cium score was 314 (28-1147) Agatston units.
The main finding was an independent association
between aortic valve TBRmax and the presence of high-
risk coronary plaque on multivariable linear regression
(b = 0.56, P = .029) after adjusting for age, sex, coronary
risk factors, statin use, and obstructive coronary steno-
sis; aortic valve calcium score was the only other
Table 1. Clinical studies investigating 18F-NaF PET in valvular heart disease
Year
Design and
population Imaging Main findings































Higher 18F-NaF and 18F-FDG activity in aortic
stenosis compared to controls
Greater progressive increase in 18F-NaF with
increasing disease severity compared to 18F-
FDG
Severity of aortic stenosis correlated more
strongly with valvular 18F-NaF than extra-
valvular 18F-NaF
18F-NaF correlated with progression in aortic
valve calcium score at 2 years.















18F-NaF co-localized with tissue staining for
calcification, including regions free of
macroscopic calcification
18F-NaF correlated with progression in aortic









Optimized 18F-NaF PET-CT analysis














18F-NaF independently associated with more
rapid bioprosthetic valve deterioration over 2
years. All patients who developed new
bioprosthetic dysfunction had 18F-NaF uptake
at baseline
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independently associated covariable. Aortic valve
TBRmax was 1.60 ± 0.18 in patients with high-risk
coronary plaque and 1.42 ± 0.13 in those without. Aortic
valve TBRmax had a modest correlation with baseline
aortic valve calcium score (r = 0.54, P = .005). In the 11
patients who had follow-up CT scans, aortic valve
TBRmax correlated strongly with change in aortic valve
calcium score (r = 0.74, P = .009).
COMMENTS
In this interesting imaging substudy of patients with
coronary plaque and subclinical aortic valve calcifica-
tion, the investigators have demonstrated a modest
correlation between aortic valve 18F-NaF and the
presence of high-risk coronary atherosclerosis. In the
context of this small post hoc analysis, the pathophys-
iological implications of this observation are uncertain.
It may reflect similarities between the early stages of
aortic stenosis and coronary atherosclerosis. However,
both conditions are common and become more prevalent
with increasing age, while high-risk plaque features on
CTCA are frequently seen in patients with coronary
atherosclerosis (e.g., 676/2890 and 608/1123 patients in
the PROMISE and SCOT-HEART randomized con-
trolled trials, respectively).16,17 Although calcium
metabolism is a key process in both aortic stenosis and
coronary artery disease, its role in the complex mech-
anisms governing these processes may differ. Therefore,
while the present study demonstrates the co-existence of
aortic valve microcalcification and high-risk coronary
plaque, further inferences remain speculative at this
stage.
Importantly, the authors do provide further evidence
that baseline aortic valve 18F-NaF PET activity predicts
progression of valve calcification. Notably, this corre-
lation was observed in a cohort of patients without aortic
stenosis, albeit in a subset of the study cohort. These
results are in keeping with the existing body of obser-
vational data to date (Table 1) and suggest that 18F-NaF
PET may be helpful in identifying the minority of
patients with aortic sclerosis who go on to develop
obstructive stenosis. Larger studies are required to
consolidate this finding, while the implications of
radiation exposure in this otherwise healthy patient
group need to be considered.
This was a retrospective analysis of a small cohort,
and the usual caveats apply. Additionally, there was also
a preponderance of males (80%), which leaves open the
question as to whether findings would be reproducible in
both men and women—an important point, given the
increasing appreciation of gender disparities in the
pathophysiology and clinical presentation of aortic
stenosis.18,19
Several points should be noted about the imaging
analysis undertaken. The authors did not include the
presence of spotty calcification or the napkin-ring sign,
well-described adverse coronary plaque characteris-
tics,20 in their analysis. Furthermore, aortic valve 18F-
NaF uptake was measured only in regions of visual
valve calcification on CT; the highest maximum stan-
dardized uptake value of these regions of interest was
used to calculate the TBRmax. This method may miss
18F-NaF uptake in regions of the valve that do not have
visually apparent calcification.13,14 Previous data have
explored the optimum method of quantifying aortic
valve 18F-NaF, demonstrating a most diseased segment
technique that incorporates regions of interest around the
entire valve area in en face slices to be the most
reproducible, correlating strongly with native and bio-
prosthetic valve disease progression.14,15,21 Here, the
authors demonstrate a similarly good level of interob-
server agreement with their technique. Ultimately,
validation against clinical outcomes will be required to
demonstrate the incremental benefit of this imaging
modality and the various image analysis techniques.
CONCLUSION
Nakamoto et al have added to the growing body of
literature investigating the associations between baseline
vascular 18F-NaF uptake and calcification progression
and highlighted a potential association with high-risk
coronary plaque. The mechanisms and clinical implica-
tions of these correlations require further prospective
research, interest in which is rightly engendered by these
early observational studies.
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